Kathy Giusti is the Founder and Chief Executive Officer of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC). In 1998 following her diagnosis with multiple myeloma, she founded the MMRF to fund innovative myeloma research and drug discovery. Having raised more than $110 million to date, the MMRF is the world's number one funder of myeloma research. As an extension of the MMRF's mission, she founded the MMRC in 2004 to enable leading research institutions to work with industry to speed the discovery and development of effective new treatments. Comprising 15 leading research institutions, the MMRC is widely recognized for breaking down barriers in tissue banking, data management, genomics, and clinical trials, and is considered an optimal research model to accelerate the development of new therapies. Ms. Giusti received her MBA in general management from Harvard Business School and graduated from the University of Vermont magna cum laude with a BS in biological sciences. She began her career in 1980 with Merck & Co., and later joined the Gillette Company. In 1993, she joined G.D. Searle & Co., where she last served as Executive Director of Searle's worldwide arthritis franchise. Ms. Giusti received the 1998 Healthcare Businesswomen's Association's Woman of the Year Award, the 2001 Harvard Business School Entrepreneurial Award, the 2002 McCarty Cancer Foundation Humanitarian Award, the 2002 Joseph Michaela Award from the Weill Medical College of Cornell University, the 2005 Harvard Business School Award for Courage and Valor, and the 2006 Partners in Progress Award from the American Society of Clinical Oncology. She has served on the Institute of Medicine's National Cancer Policy Board and the Cancer Leadership Council. Today, she continues to serve on the National Cancer Advisory Board, an appointment she received in 2003 from President Bush, and is a member of the Board of Directors for IMS Health as well as the Health Research Alliance. Most recently, her efforts to advance cancer research and drug development have been featured in The Wall Street Journal, "NBC Nightly News", CBS Evening News and The New Yorker. She lives in New Canaan, CT, with her husband, Paul, and her children, Nicole, who is 13, and David, who is 11.

Profiles:

Scott Santarella is the Executive Director and Chief Operating Officer of the MMRF and MMRC, where he oversees the organizations' daily operations, strategic business planning, fundraising, research spending, programming, and public awareness efforts. In Scott's eight-years as Executive Director, the MMRF has seen its annual revenue grow 246%, while maintaining administrative and fundraising expenses at a combined 5%. Scott has been instrumental in the MMRF being recognized as an A+ charity by American Institute of Philanthropy – the only cancer-based organization which such distinction – and under his leadership the MMRF has received a 4-star rating from Charity Navigator for four consecutive years. Scott's career experience spans the spectrum of the non-profit industry, from national fundraising for the March of Dimes, to international marketing and communication for the Knights of Columbus, to grassroots development with the Center for Environmental Activities, grant-making for the Educational Foundation of America. Scott received his Executive Leadership Certification from Harvard Business School in 2006. He graduated cum laude from the University of Massachusetts at Amherst with a BA in journalism.

Susan L. Kelley, MD, is Chief Medical Officer of the Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC), where she provides senior medical leadership for the clinical development activities supported by the MMRC. Dr. Kelley has more than 20 years of experience in oncology clinical research and drug development within the pharmaceutical industry. Dr. Kelley most recently served as Vice President of Global Clinical Development for Oncology at Bayer Healthcare Pharmaceuticals, where she was responsible for the management of the oncology drug development portfolio and for the supervision of Bayer's oncology physicians and clinical project managers. While at Bayer, she oversaw the successful advancement of Nexavar (sorafenib) through the FDA approval process. Prior to her position at Bayer, Dr. Kelley held several leadership positions in Bristol-Myers Squibb's (BMS) Oncology Therapeutic Area. While at BMS, she participated in the development and registration of several new drug products, including Vumon (teniposide), Taxol, and Videx (didanosine); she also supervised clinical development programs for a cancer vaccine for melanoma and numerous phase I and II clinical trials. Dr. Kelley received her medical degree from Duke University School of Medicine. She completed certification in Internal Medicine at University of Colorado followed by Medical Oncology training at the Dana-Farber Cancer Institute in Boston.

Louise M. Perkins, PhD, is the Chief Scientific Officer at the MMRF where she is responsible for the strategic development and execution of the MMRF's research agenda. Dr. Perkins brings more than 16 years of pharmaceutical research experience from 2 major companies to the MMRF. Prior to joining the MMRF, she was the Director of Cancer Research at Bayer Pharmaceuticals in West Haven, CT, where she contributed to advancing novel targeted therapies toward clinical study, including Nexavar® and other innovative signal transduction inhibitors. While at Bayer, she also served as the Director of Research Licensing and was responsible for oncology licensing activities in support of cancer research programs. Prior to joining Bayer, she led a cancer research group at the Schering–Plough Research Institute in Kenilworth, NJ. In this role, she participated in several early-stage research programs including novel target-finding research using human genomics data. Dr. Perkins graduated from the University of Michigan with a PhD and MS in biological chemistry and conducted postdoctoral studies at Princeton University in the Department of Molecular Biology. She earned her BS in zoology from the University of North Carolina at Chapel Hill.

Anne Quinn Young is Program Director at the MMRF, where she oversees all communications as well as educational programming for and outreach to healthcare professionals and patients. Anne currently serves as the MMRF's representative on the Cancer Leadership Council (CLC) and as principal investigator on a major grant from the Centers for Disease Control and Prevention (CDC). Prior to joining the MMRF, Anne was a consultant in the Healthcare Practice of Datamonitor, a global market research and business intelligence company. Anne previously worked in healthcare public relations at Burson-Marsteller and Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division. Anne has a Master of Public Health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a BA in government.

Anne M. Walker is National Events Director at the MMRF, where she oversees the Foundation's national event strategies plan and its regional organizational expansion plan. Anne brings to the MMRF an extensive entrepreneurial background, as well as a proven track record in event management and fundraising. Anne began her career as an institutional equity sales trader at Morgan Stanley and Company. Prior to joining the MMRF, Anne was co-founder and CEO of Nearwater Event Group, an event consulting firm. Previous to this, Anne served as managing director of Greenfield Healthy Foods Company. Anne has been active in fundraising and event organization as a volunteer with a wide range of groups, including the Center for Hope, Darien Public Schools, Bucknell University and Norwalk Hospital. Anne graduated from Bucknell University with a BA in economics.

Jennifer Katritos is Director of Finance at the MMRF and MMRC. She has more than 15 years experience in both public and private accounting. Prior to joining the MMRC and MMRF, Jennifer was an associate with PricewaterhouseCoopers and previously held positions at Unapix Entertainment, Inc., M.R. Weiser & CO, and Deloitte & Touche. Jennifer received her BS in accounting from the State University of New York at Oneonta.

Joan Levy is Associate Director of Research at the MMRF, where she is responsible for the planning and implementation of the Foundation's research agenda. She has more than 20 years of experience in oncology and osteoporosis research in both pharmaceutical and academic settings. Prior to joining the MMRF, Joan was Technical Director at the Binding Site, where she supported the use of Freelite, a diagnostic assay for multiple myeloma. Previous to this, Joan was worked for nine years with Bayer Pharmaceuticals, where she was engaged in target identification, compound validation, and project leadership. Joan's experience also includes research in cell biology, orthopedics, and pharmacology at Yale University and New York University Medical Center. She earned her PhD in biochemistry from the University of Vermont and completed post-doctoral fellowships at Rockefeller University and State University of New York (SUNY) at Stony Brook. She received her BS in biology from SUNY Stony Brook.

Theresa M. Lyons, MS, MS, PhD, is the Development Manager at the MMRF, where she is responsible for the expansion of efficient and effective development programs to enhance cultivation and reinvestment of the MMRF annual revenue budget. Prior to joining the MMRF, Dr. Lyons was a Medical Strategist at 81qd, a health care consulting company, in which she was the lead scientific person for new business development, procurement, and various projects consulting on drug life cycle management. She has experience in identifying Key Opinion Leaders (KOLs), physician influence mapping, sentiment analysis, market research, and message mapping. She has worked on projects in numerous therapeutic areas including oncology and immunology. Dr. Lyons received her doctorate in computational chemistry from Yale University and completed her postdoctoral fellowship at sanofi-aventis. She holds a master's degree in synthetic organic chemistry from St. John's University and a master's degree in chemistry from Yale University.